SG/CALL/MODERNA/110/0.1/20.09.24 | Real-time Euronext Paris 07:05:16 2024-06-20 EDT | ||
| 2.775 EUR | +3.74% |
|
| Current month | -25.49% | ||
| 1 month | -7.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 2.775 | +3.74% |
| 24-06-19 | 2.675 | -7.76% |
| 24-06-18 | 2.9 | -11.31% |
| 24-06-17 | 3.27 | -1.51% |
| 24-06-14 | 3.32 | -13.20% |
Real-time Euronext Paris
Last update June 20, 2024 at 07:05 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| U567S | |
| ISIN | DE000SU670W9 |
| Date issued | 2024-01-22 |
| Strike | 110 $ |
| Maturity | 2024-09-20 (93 Days) |
| Parity | 10 : 1 |
| Emission price | 1.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.87 € |
|---|---|
| Lowest since issue | 0.725 € |
| Spread | 0.05 € |
| Spread % | 1.79% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Warrants
- U567S Warrant
